





BIO  
INTERNATIONAL  
CONVENTION

**BOSTON**

Convention & Exhibition Center  
Boston, MA (USA)

june **5-8** 2023







BIO INTERNATIONAL CONVENTION  
BOSTON 2023



**SPAIN PAVILION**  
**443**




1. ADL Biopharma
2. A4Cell
3. Ascil Biopharm
4. BCN Peptides
5. Bioingenium
6. Biomar
7. CancerAppy
8. BeCytes Biotechnologies
9. CZ Vaccines
10. Fastbase Solutions
11. Genomcore
12. Grifols Engineering
13. i+Med
14. Inves Biofarm
15. Laminar Pharmaceuticals
16. Remab Therapeutics
17. Tecnic Process
18. Canarias ZEC
19. 24Genetics




# ALPHABETICAL INDEX OF EXHIBITORS

1.	24Genetics	11
2.	A4cell	12
3.	Acellera	13
4.	ADL Biopharma	14
5.	Ahead Therapeutics	15
6.	Anaxomics Biotech	16
7.	Arthex Biotech	17
8.	Ascil Biopharm	18
9.	BCN Peptides	19
10.	BeCytes Biotechnologies	20
11.	Bioingenium	21
12.	Biomar Microbial Technologies	22
13.	Canary Island Special Zone Consortium	23
14.	CancerAppy	24


15.	Cebiotex	25
16.	Celldrive 3D	26
17.	Cocoon Bioscience	27
18.	Connecta Therapeutics	28
19.	CZ Vaccines	29
20.	Genomcore	30
21.	GP Pharm	31
22.	Grifols Engineering	32
23.	Hawk Biosystems	33
24.	i+Med	34
25.	Innoprot	35
26.	InnoUp Farma	36
27.	Inves Biofarm	37
28.	Invest in València	38
29.	Laboratorios Farmacéuticos ROVI	39
30.	Laminar Pharmaceuticals	40
31.	Libera Bio	41
32.	Nanoligent	42
33.	Oniria Therapeutics	43
34.	Operon	44
35.	Remab Therapeutics	45
36.	Tecnic Bioprocess Equipment Manufacturing	46




# Companies & sectors



## Companies & sectors




# Pharmaceutical Development



# Diagnostic

Basic Research Pilot product Validation assays In market





## EXHIBITING COMPANIES BOOTH 2023

### 24Genetics

Nacho Esteban

**Founder and CEO**

nacho@24genetics.com

www.  
24genetics.com



Direct to Consumers DNA test including: ancestry, nutrigenomics, PGx, health prevention, sports, skin care, longevity, personality and microbiome.

**Trademarks:**

24Genetics

Life is DNA

CrossDNA

Ancestrum

GalaxyDNA



## A4cell

Elena Rivas Pérez  
**CEO**

info@a4cell.com  
(+34) 910 679 519

www.  
a4cell.com



A4Cell provides cell assays for living single cell imaging based on the concept of lab-in-a-cell. With SPACHIP® technology you can detect biomolecules by fluorescence analysis during several days in the same cell culture at different time points for metabolic and phenotypic studies. SPACHIP® devices are silicon oxide microparticles functionalized with fluorescent detection probes for intracellular monitoring of living single cells to improve the quality and accuracy of outcomes to cell studies in order to better understand diseases behaviour.

**Trademarks:**

Cytocheck SPACHIP®

## Acellera

Franck Chevalier  
**Head of Business Development**

info@acellera.com

www.  
acellera.com



Acellera's mission is to enable computable drug discovery, developing the algorithms to automate drug discovery via high-throughput computations and machine learning methods. Our proprietary technology provides the capabilities to simulate proteins and small molecules with atomic precision to obtain new hypotheses, data and knowledge. Machine learning is used to extract information over large, high-dimensional datasets and to direct machine learning-informed physics models.

Our business model includes scientific and technological partnerships in drug discovery. Early drug discovery services and software licensing are available as well.

Our approach is based on a strong expertise and unique protocols focusing on the deep and complete structural study of protein and nucleic acid targets.

**Trademarks:**

ACEMD™, ACCELLERA™, PLAYMOLECULE™, PLAY™ blockchain token



## ADL Biopharma

Luis Sanz de la Serna  
**Strategy & Corporate Development**

lsanzdelaserna@adlbiopharma.com  
(+34) 682 381 228

www.  
adlbiopharma.com



ADL BioPharma is a Spanish company specialised in third party manufacturing and development (CDMO) with two business lines: precision fermentation and purification and synthesis of sterile oral antibiotics. The company has the know-how of more than 60 years of operations and has the largest fermentative capacity in Southern Europe as well as a state of the art pilot plant to scale-up customer innovations.

## Ahead Therapeutics

Martí Dalmases  
**CEO**

marti.dalmases@aheadtherapeutics.com

www.  
aheadtherapeutics.com



Ahead Therapeutics is a biotech company developing drugs to treat autoimmune diseases. It has a proprietary technology platform to generate antigen-specific immune tolerance.

**Trademarks:**

AHEAD THERAPEUTICS

## Anaxomics Biotech

Mireia Coma  
**Medical Director and Business  
Development Director**

mcoma@anaxomics.com  
(+34) 648 789 862

[www.  
anaxomics.com](http://www.anaxomics.com)



Global leader specialized in the application of Machine Learning and Systems Biology to overcome challenges in pre-clinical and clinical research and add support to key decisions across the drug discovery and development process. Some of our applications:

- Perform In Silico Clinical Trials
- Elucidate the mechanism of action of drugs
- Discover new biomarkers
- Identify combinatorial therapies, new therapeutic targets, and new indications for existing drugs
- Early profiling of safety issues and off-target effects
- Support decisions in in- and out-licensing processes

## Arthex Biotech

Dr. Frédéric Legros  
**Chairman**

flegros@arthexbiotech.com

[www.  
arthexbiotech.com](http://www.arthexbiotech.com)



Clinical stage company developing microRNA modulators for diseases with high unmet medical needs.

Our most advanced lead (ATX-01) is focused on a first-in-class therapy for myotonic dystrophy type 1 (DM1).

ATX-01 is a dual therapeutic approach targeting the genetic cause of DM1 (toxic DMPK and MBNL proteins).

ATX-01 IND/CTA submission expected mid 2023.

Phase 1/2 trial with clinical readouts expected in 2024.

### **Trademarks:**

Arthex Biotech  
ArthemIR



## Ascil Biopharm

Pierre Cherif-Cheikh  
**Business Development Manager**

bd@ascil-biopharm.com

www.  
ascil-biopharm.com

in

Ascil is a clinical stage Drug Delivery System company with products ready for licensing or co-development. Formed in 2012, our first business unit is internal projects of controlled-release formulations and medical device projects. The second business unit is R&D and CDMO services for non-GMP or GMP operations, with manufacturing capabilities for early-phase clinical batches (parenteral products).

We are settled in a 1500 m2 building fully equipped for pharmaceutical development. We have a proven track record of developing injectable solutions with hundreds of DDS formulations and device patents. We can support partners on slow-release formulations, ultra-high concentrations, and low or extremely high viscous injectable solutions, finding ways to use thin needles.

## BCN Peptides

Dr. Jordi Piró  
**Global Sales Director**

info@bcnpeptides.com

(+34) 938 191 399

www.  
bcnpeptides.com

in

BCN Peptides is completely focused on the GMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications.

- Synthesis of API Peptides.
- Production of Peptides for Personalized Medicine.
- Proprietary R&D Products into diabetic retinopathy, neuropathic and inflammatory pain and autoimmune diseases.

Excellent GMP compliance: PMDA, US-FDA and EDQM Approved. Furthermore, we develop therapeutically promising peptides to solve unmet needs on different indications.



BeCYTES  
BIOTECHNOLOGIES S.L.

bioingenium  
.

## BeCytes Biotechnologies

Estephan Arredondo  
**Technical Director**

earredondo@cytesbiotechnologies.com  
(+34) 93 403 45 53

www.  
becytesbiotechnologies.com

in

BeCytes specializes in providing customized solutions for life science researchers to progress in preclinical research and improve human health. Our services include sourcing human tissue, primary hepatic cells, and related solutions, catered to meet each client's unique needs. Our clients include renowned pharmaceutical and biotechnology companies, academic institutions, and contract research organizations worldwide. Our team collaborates closely with researchers to ensure the highest quality results using state-of-the-art technologies and methodologies. We are committed to providing exceptional solutions that support successful studies.

### Trademarks:

BeCytes Biotechnologies

## Bioingenium

David Resina Rodriguez  
**CEO**

dresina@bioingenium.net  
(+34) 93 402 02 40

www.  
bioingenium.net

in

Bioingenium is a CDMO that offers tailor-made bioprocess services.

Our main business units are:

- Biopharmaceutics: biologics, vaccines, antibodies, therapeutic proteins for human and animal health based on E.coli, CHO, HEK or Pichia expression systems. Bioprocess development and scale up, proof of concept to transfer to a GMP plant.
- Cosmetics: We develop and manufacture innovative active ingredients based on natural ferments.
- Food: industrial enzymes and alternative protein development, setup and production.

We also manufacture high purity recombinant Streptolysin O antigen for research and diagnostic manufacturing.



## Biomar Microbial Technologies

Miguel Fernandez Medarde  
**Business Development Manager**  
m.fernandez@biomarmt.com  
(+34) 987 849 200

www.  
biomarmt.com



Biomar offers unique libraries of 80.000 strains, 70.000 microbial extracts and 1200 pure natural compounds ready to use for different applications. The diversity of these collections, together with Biomar's team technical experience and expertise in project design and execution, are used for the development of products and processes.

Biomar also offers production by fermentation in its plant with volumes up to 3.000L, including the downstream equipment required for different applications: biomass recovery, extraction and, if necessary, purification of bioproducts.

## Canary Islands Special Zone Consortium

María Delia Domínguez Montenegro  
**Técnico Superior/ Senior Consultant**  
dmontenegro@canariaszec.gob.es  
(+34) 630 805 583 / 928 490 582

www.  
canariaszec.com



Canary Island Special Zone is a tax advantage passed by the Spanish Ministry of Tax and the E.U. Commission. Our purpose is the attraction of companies that want to develop a substantial activity in the Canarias Archipelago, such as the process/ trade of nutraceutical ingredients or any biological product or service. In exchange of settling in our territory, the ZEC Entity will enjoy a reduced type of rate (only 4%) at Spanish Corporate Income Tax, among other advantages, such as no withholding tax at returning dividends, or paying interests and royalties to parent companies based anywhere, E.U. or third countries (fulfilling the conditions in E.U. parent company Directive: 5% ownership during one year)

## CancerAppy

Luis Martin  
**CEO**

[l.martin@cancerappy.com](mailto:l.martin@cancerappy.com)

[www.cancerappy.com](http://www.cancerappy.com)



CA04 - First-in-class antibody against CA04 which is a Transmembrane Protein, Currently no Antibody exist against CA04, No clinical candidate has been nominated for this target.

Status: High specificity of the antibody in the preclinical phase in vitro. Beginning in vivo trials.

CA05 is a Protein Kinase overexpressed in several tumor types, CA05 - First-in-class Kinase inhibitor.

CA05 has a clear oncogenic role, No clinical candidate has been nominated, CA05-KI is a first in class kinase inhibitor identify by our proprietary AI platform.

Status: In vitro tests with positive results. Improved compounds and test with encapsulation.

## Cebiotex

Joan Bertran Llavina  
**CEO & Founder**

[info@cebiotex.com](mailto:info@cebiotex.com)

[www.cebiotex.com](http://www.cebiotex.com)



Cebiotex is an innovative clinical stage start-up, spin-off of the Sant Joan de Déu Hospital (HSJD) and the Universitat Politècnica de Catalunya (UPC) all based in Barcelona (Spain).

Cebiotex current mission is to provide solutions to patients with cancer, adult and paediatric, through its CEBIOTEX® Technological Platform patented in US, EU, China and Japan (last one in process).

First drug in Ph1 clinical development, CEB-01, is an innovative pharmaceutical product for Soft Tissue Sarcomas (STS) local control after tumour removal. [Clinicaltrials.gov NCT04619056](https://clinicaltrials.gov/ct2/show/study/NCT04619056).

Future perspective is to provide solutions in other cancer indications and therapeutic applications.



## Celldrive 3D

Isabel Jiménez  
**COO**

isabel.jimenez@celldrive3d.com

www.  
celldrive3d.com

CellDrive 3D offers a modular technology to develop translational bioinks for 3D bioprinting, the only synthetic bioinks capable of promoting cell adhesion and removal while remaining stable after printing without using crosslinkers or photoinitiators.

CellDrive 3D features a one-of-a-kind bioink platform obtained through genetic engineering techniques to create living tissue on demand. Its formulation, free of animal components, mimics the extracellular matrix, maximizing the cell viability of embedded cells and 3D resolution. This bioink stands out mainly for its printability and biocompatibility.

## Cocoon Bioscience

Josh Robinson  
**CEO**

jrobinson@cocoonbioscience.com  
(+34) 657 046 885

www.  
cocoonbioscience.com

in

Cocoon Bioscience is an enzyme manufacturing company that leverages insects in their cocoon state as natural bioreactors on an automated production platform. Our primary focus, to date, has been on enzymes that modify or synthesize nucleic acid.

Our platform has repeatedly demonstrated the ability to manufacture enzymes with superior performance at a cost point significantly lower than traditional methods with high quality standards.





## Connecta Therapeutics

Jordi Fàbrega Casadellà  
**Co-Founder & CEO**

[www.  
connectatherapeutics.com](http://www.connectatherapeutics.com)



CONNECTA Therapeutics is a clinical stage biotechnology company developing new treatments for unmet CNS medical needs.

The company is focused on its new first-in-class molecule, CTH120, a neuroplasticity modulator with therapeutic applications in neurodevelopmental disorders. CTH120 is currently being developed for the treatment of fragile X syndrome (FXS), the most common cause of hereditary intellectual disability with currently no therapeutic interventions available.

All ADME and toxicology studies have been completed and phase I clinical trials are being performed in 2023.

## :CZ VACCINES

## CZ Vaccines

Mercedes Rodriguez  
**Commercial Director**  
**CDMO Human Biologicals**

[Mercedes.rodriguez@czvaccines.com](mailto:Mercedes.rodriguez@czvaccines.com)  
(+34) 630 456 502

[www.  
czvaccines.com](http://www.czvaccines.com)



CZ Vaccines is an ideal partner for any organization intending to advance their biologic product candidates from development scale to clinical Phase I to III, and commercial supplies capability.

Your partner for BIOLOGICS manufacturing

- Live & Inactivated Bacteria & Viral Vaccines up to BSL-2
- Sterile processing systems
- Process Development / Optimisation (Upstream / Downstream)
- Scale-up and cGMP manufacturing
- Aseptic filling into vials
- Lyophilization (clinical trial material and large scale)
- Quality control testing: Microbiological: Sterility-non-sterility, Chemical-Physical and Biological
- Labeling & packaging
- DS & DP release
- Storage: (+2-8°C), (-30°C), (-80°C) setup and production.





## Genomcore

Multimodal data store and low-code solutions builder for precision health.

**Trademarks:**

Genomcore  
Made of Genes

Miquel A. Bru  
**Co-Founder and VP Sales & MK**  
miquel.bru@genomcore.com  
(+34) 717 714 400

www.  
genomcore.com



## GP Pharm

GP Pharm is a pharmaceutical company specialized in the development and manufacturing of complex / high-value / niche injectable products. Our products are based on the use of peptide APIs and/or in-home developed drug delivery systems (Microspheres and Liposomes). GP Pharm has its GMP approved manufacturing facilities located in Barcelona (Spain). The activities of the company are focused towards out-licensing of our products, CDMO services and marketing activities in Spain through our own sales force.

Alex de la Fuente  
**Business Development Director**  
adelafuente@gp-pharm.com

www.  
gp-pharm.com



## Grifols Engineering

Oriol Mora  
**Director, External Projects MGMT**

Info.ge@grifols.com

www.  
grifolsengineering.com

Grifols Engineering specializes in the field of biopharmaceutical engineering. We develop and execute projects for Grifols manufacturing sites and external clients to serve production needs with highest quality and safety. We design biotech factories, cleanrooms and process equipment, we construct machinery and robotic systems to improve the implementation of process automation and reduction of human impact. We have acquired the experience and know-how over the course of several decades by developing in-house process, facility projects and special machinery for Grifols manufacturing. Our machinery and industrial facilities are designed to comply with European Medicines Agency in Europe and Federal and Drug Administration in the USA.

## Hawk Biosystems

James Miles  
**Product Manager**

james.miles@hawkbiosystems.com  
(+34) 94 640 55 20

www.  
hawkbiosystems.com



HAWK Biosystems have developed a groundbreaking bio-imaging platform, QF-Pro® which detects protein-protein interactions and protein post-translational modifications directly within patient pathology samples. QF-Pro® can be applied to any biomarker or disease state, however, it is particularly potent in its ability to stratify lung cancer patients to receive ICI therapies, where it can triple patient responses and double survival. HAWK Biosystems are launching Violet 3.0, a bespoke device for running QF-Pro® assays in the life sciences market, alongside QF-Pro® reagent kits.

## i+Med

Miguel Ucelay López de Heredia  
**Marketing Manager**

miguel.ucelay@imasmed.com  
(+34) 945 561 134

www.  
imasmed.com/en



i+Med is a biomedical engineering company devoted to the research, development and manufacturing of biomedical devices and innovative medicines with high added value. A cooperative of scientists positioned as one of the world leaders in the field of nanohydrogels and controlled release. We are specialists in the development of smart nanohydrogels and controlled release of active ingredients. We apply our expertise around different technologies, supported by our 5 patents, thus customising different solutions tailored to our client's needs.

### Trademarks:

i+Med, TrHCROSS, OpHLINE, BtHLINE, BtHCROSS, Daydrop, Buddydrops, Profilm, Revodiol.

## Innoprot

Jorge Gamiz  
**Business Development Director**

innoprot@innoprot.com

www.  
innoprot.com



Innoprot provides products and technologies for multiplexing cell-based assays in drug discovery and development. With a proprietary technology for GPCR screening, Innoprot is able to identify the compounds with the highest effectiveness but avoiding the undesired side effects. Innoprot also acts as a C.R.O. providing screening services focused on GPCRs, Fibrosis and Neurodegenerative diseases like Alzheimer's Disease, Parkinson's Disease or ALS.

## InnoUp Farma

Elisa Longás  
**Chief Business Officer**

elongas@innoupfarma.com  
(+34) 717 714 400

www.  
innoupfarma.com



Oral immunotherapy for peanut allergy.  
Oral chemotherapy for breast cancer.

## Inves Biofarm

Teo Mayayo  
**Director**

inveskinusa@invesbiofarm.com

www.  
invesbiofarm.com



We have a patent for protein stabilization valid for pharmaceuticals, medical devices and cosmetics that results in products with greater differential efficacy in atopic dermatitis, acne, and wound healing (Clinical studies). We are also a Spanish CMO specialized in medical devices and cosmetics, our facilities are fully equipped to produce liquid, semisolid, and sterile products (syringes, ampoules, vials, eye drops). We offer an end-to-end service from design, development, formulation, manufacturing, and regulation of medical devices and cosmetics.

### **Trademarks:**

Inveskin, Wiotech, Invesderm.

## Invest in València

Virginia Garcia  
**Project Manager**

vgarcia@investinvlc.com  
(+34) 963 103 900

www.  
investinvlc.com



The Invest in València Office is a joint initiative of the València City Council & the Valencia Chamber of Commerce. We attract investment and support all investment processes of companies and investors interested in the city, providing different kinds of tailored advisory services. We have 3 main lines of action, which vary in accordance with which stage the company/investor is at: attraction, establishment and aftercare. We are a publicly funded organization and our services are free of charge.

## Laboratorios Farmaceuticos ROVI

Lucía Morillo  
**Business Development Manager**

bd@rovi.es

www.  
rovi.es



ROVI is a public pan-European company (ticker: ROVI) with a market cap of around 2 B EUR and revenues of 820 M EUR in 2022. ROVI's HQ are based in Madrid, Spain and we have direct presence in Germany, France, UK, Italy, Portugal, Poland and Austria.

Risvan® is a new highly efficacious and well-tolerated monthly LAI treatment for unstable Schizophrenia patients with severe and moderate symptoms undergoing a relapse and for the long-term treatment. It's under review by FDA and approved by EMA.

### **Trademarks:**

RISVAN/OKEDI

## Laminar Pharmaceuticals

Victoria Lladó Cañellas  
**General Manager US**

[Victoria.llado@laminarpharma.com](mailto:Victoria.llado@laminarpharma.com)

[www.laminarpharma.com](http://www.laminarpharma.com)



Laminar Pharmaceuticals is a pioneering biopharmaceutical company focused on drug discovery, rational design and clinical development. All our compounds are based on a novel therapeutic approach: Membrane Lipid Therapy (Melithery), which focuses on targeting and normalize membrane lipids. Our objective is to provide a solution to serious diseases with unmet clinical needs, such as glioblastoma, where our most advanced compound is in a pivotal Phase 2/3 clinical trial for approval and possible commercialization.

## Libera Bio

Olivier Jarry  
**CEO**

[Olivier.Jarry@LiberaBio.com](mailto:Olivier.Jarry@LiberaBio.com)  
(+34) 914 703 1073

[www.liberabio.com](http://www.liberabio.com)



Therapeutic antibodies delivered intracellularly by proprietary Multifunctional Polymeric Nanocapsules (MPN).

Lead candidates: MPN-antiKRAS G12D and G12V. Four others in early development. Initial focus on cancer.

Open to alliances (several in progress) with:

- Biotech and institutions designing biologics for intracellular targets.
- Antibody developers.
- Biopharma for late-stage development and commercialization.

### **Trademarks:**

Libera Bio ®

MPN Technology ®

## Nanoligent

Manuel Rodríguez Mariscal  
**Chairman**

[www.  
nanoligent.com](http://www.nanoligent.com)



Nanoligent is a biotech company developing one-of-a-kind drug able to selectively kill cancer cells responsible of metastasis. It is a new biotechnological platform directed to treat very aggressive CXCR4+ cancer types, more than 40% of the patients of 23 different metastatic cancer types. We have a selected preclinical candidate progressing to IND. Our pre-clinical data shows that, upon administration of our drug in several cancer mouse models of metastasis, our nanomedicine accumulates in primary tumor and in metastatic tissues, with no detectable uptake in liver, kidney, brain, and other healthy organs.

## Oniria Therapeutics

Esther Riambau  
**Chief Executive Officer (CEO)**

[erriambau@oniriatherapeutics.com](mailto:erriambau@oniriatherapeutics.com)  
(+34) 620 006 316

[www.  
oniriatherapeutics.com](http://www.oniriatherapeutics.com)



Oniria Therapeutics is a biopharmaceutical company in the field of precision oncology. It develops first-in-class therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence.

Our flagship product, ONR-001, is an oral small molecule that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter a dormant state and even die.

### **Trademarks:**

Oniria Therapeutics





## Operon

Tomás Toribio Renner  
**Managing Director**

Sales@operon.es  
(+34) 976 503 597

www.  
operondx.com



We are a spanish biotechnological company with 50 years of experience in R&D and Manufacturing of IVD products. Nowadays, we are exporting our products to more than 50 countries all over the world. Our main product lines are: immunochromatography – rapid test, molecular diagnostics (Opegen products and Real Time), raw materials (monoclonal antibodies and recombinant antigens), and customized products/services.

**Trademarks:**

OPERON  
OPEGEN

## Remab Therapeutics

Pablo Madrazo  
**CEO**

info@remabtx.com

www.  
remabtx.com



RemAb Therapeutics is a company developing molecules for the intracorporeal removal of harmful antibodies. The company pipeline includes molecules to remove antibodies in allergic and autoimmune diseases, anti-ABO blood group antibodies, antibodies neutralizing adenoviruses used for gene therapy, and antibodies acting as enhancers of infections. We are at the clinical stage for the latter indication, specifically for preventing nosocomial Gram-negative infections, including those resistant to antibiotics.



# Tecnic

## Bioprocess Equipment Manufacturing

Ofir Chinchilla

**Area Manager Sales Application Solution**

ofir.chinchilla@tecnic.eu

(+34) 619 768 265

www.  
tecnic.eu

in

TECNIC, designs and produces laboratory, pilot, and production-scale equipment for the biotech and pharmaceutical industries. With extensive experience in 3D design, stainless steel processing, machinery, and assembly, their End-to-End working method ensures excellence in their products. They also have BSL2 laboratories for cell and microbial culture, providing differential support to customers. Their multidisciplinary team comprises engineers, biotechnologists, biologists, and expert technicians.

**Trademarks:**

TECNIC





# Spain

**Trade Commission of Spain**  
500 North Michigan Avenue, Suite 1500  
Chicago, IL 60611, USA  
Phone +1 312 644 1154

**ICEX Spain Trade and Investment**  
Paseo de la Castellana, 278  
28046 Madrid, Spain  
Phone +34 913 497 100



e-catalogue



**ICEX**

